Status In progress
Process STA pre-2018
ID number 945

Provisional Schedule

Expected publication 03 October 2018

Project Team

Project lead Jeremy Powell

Email enquiries

Consultees

Companies sponsors Janssen-Cilag
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Prostate Cancer UK
  Tackle Prostate Cancer
Professional groups Association of Cancer Physicians
  British Association of Urological Surgeons
  British Uro-Oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord (docetaxel, bicalutamide) (not participating)
  Actavis (docetaxel) (not participating)
  AstraZeneca UK (bicalutamide, goserelin) (not participating)
  Dr Reddy’s (docetaxel) (not participating)
  Hospira (docetaxel) (not participating)
  Ipsen (triptorelin)
  Medac UK (docetaxel) (not participating)
  Orion Pharma UK (histrelin) (not participating)
  Sanofi (docetaxel) (not participating)
  Seacross (docetaxel) (not participating)
  Sunpharma (bicalutamide) (not participating)
  Takeda UK (leuprorelin) (not participating)
  Zentiva (bicalutamide) (not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute

Timeline

Key events during the development of the guidance:

Date Update
06 June 2018 - 27 June 2018 Appraisal consultation: 1
10 May 2018 Committee meeting: 1
05 December 2017 Invitation to participate
10 May 2017 Please note that following on from advice received from the company this appraisal has been rescheduled. Therefore, we now anticipate that the appraisal will begin during mid November 2017 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late January 2018.
09 May 2017 Draft scope documents
22 July 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance